Compare Dow Inc (DOW) vs 10X Genomics Inc (TXG) Price & Performance

DOW trades at $30.37, up 4.62% on the day, with a bullish technical signal from moving averages despite negative profitability metrics. The company reported a net loss of $2.62 billion for 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Dow's inclusion in discussions about materials stocks benefiting from oil price spikes, while cash flow trends show improved net cash generation in 2025.

The outlook is mixed: analyst consensus suggests 19% upside to the $36.11 price target, but high P/E of 75.93 and negative margins pose valuation risks. Key opportunities include dividend payments and earnings beats, while risks involve sustained profitability challenges and rising debt-to-asset ratios nearing 30%.

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.